AgingResearch.NewsJoin free

Ropivacaine

Ropivacaine has been studied in 6 papers since 2016: 1 trial and 2 observational studies in people, 1 in animals, 1 in cells; 1 in the past year. It is an approved medicine. The newest story, Oct 23, 2026: “Sedative reduced delirium after hip fracture surgery”.

InterventionApproved 1996

6 papers study it6 more mention it4 findingsUpdated

PubChemChEBIMeSH

1 new paper in 30 daysSee all 12

None of its findings points the other way.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

About aging: trials about aging, of every trial that tests the drug for any use.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

  • 1 lab in 1 country
  • 338 trials, 1 about aging, 151 with no results posted
  • Funders: Fundamental Research Funds for the Central Universities and 3 more
  • Human trial1
  • Humans2
  • Animals1
  • Cells1

What did studies of Ropivacaine find?

4

Studies of Ropivacaine measured 4 outcomes; the most studied are STAT3 phosphorylation (1 study), VEGF-A (1) and cancer pain (1).

STAT3 phosphorylation

downin mice1

1 study

  1. Ropivacaine inhibits STAT3 phosphorylation in mice (combined with caloric restriction).

    “dual inhibition of phosphorylation of STAT3 at Tyr705 and Ser727 by Rop-DPRL and CR contribute to the reduction of VEGF-A.”

    Animalscombined with caloric restrictionliposome-loaded (Rop-DPRL)

    Combination therapy with ropivacaine-loaded liposomes and nutrient deprivation for simultaneous cancer therapy and cancer pain relief

    Theranostics

More on STAT3 phosphorylation

VEGF-A

downin mice1

1 study

  1. Ropivacaine decreases VEGF-A in mice (repeated administration combined with caloric restriction, advanced cancer mice).

    “continuous alleviation of cancer pain through reduction of VEGF-A levels in advanced cancer mice”

    Animalsrepeated administration combined with caloric restriction, advanced cancer miceliposome-loaded (Rop-DPRL)

    Combination therapy with ropivacaine-loaded liposomes and nutrient deprivation for simultaneous cancer therapy and cancer pain relief

    Theranostics

More on VEGF-A

Cancer pain

downin mice1

1 study

  1. Ropivacaine decreases cancer pain in mice (short duration, administered alone).

    “administration of Rop-DPRL could relieve cancer pain with its own analgestic ability in a short duration”

    Animalsshort duration, administered aloneliposome-loaded (Rop-DPRL)short duration

    Combination therapy with ropivacaine-loaded liposomes and nutrient deprivation for simultaneous cancer therapy and cancer pain relief

    Theranostics

More on Cancer pain

Tumor growth

downin mice1

1 study

  1. Ropivacaine decreases tumor growth in mice (combined with caloric restriction, repeated administration).

    “Replicated administration of Rop-DPRL and calorie restriction (CR) could efficiently repress the development of tumor.”

    Animalscombined with caloric restriction, repeated administrationliposome-loaded (Rop-DPRL)

    Combination therapy with ropivacaine-loaded liposomes and nutrient deprivation for simultaneous cancer therapy and cancer pain relief

    Theranostics

Has Ropivacaine been tested in people?

1 about aging, of 338

Yes: 1 trial and 2 observational studies in people have been published, and 338 trials are registered.

About aging

Approved

  • FDA Naropin

    Sep 24, 1996Acute Pain, anesthesia, cesarean section

Repurposing

40 of 104

Every condition in trials

  • Local anesthesia

    Phase 4Results posted4 trials

  • Health Condition 1: O- Medical and Surgical

    Phase 4Status unknown3 trials

  • Knee arthroplasty

    Phase 4Completed3 trials

  • Bariatric Surgery Candidate

    Phase 4Completed2 trials

  • Bites and Stings

    Phase 4Completed2 trials

  • Regional Anesthesia

    Phase 4Completed2 trials

All 25

Readouts due

All 9

Stopped

  • NCT00421967TerminatedPostoperative pain

    Interim analysis

  • NCT02788019TerminatedPostoperative pain

    Unable to complete the sample size needed for 80% power due to changes in surgical approach to adductor block usage.

  • NCT04368364TerminatedPostoperative pain

    Study was stopped early due to a conflicting study in the same patient population at the study location.

  • NCT02933671TerminatedPain

    Study halted prematurely and will not resume; participants are no longer being examined or receiving any intervention.

  • NCT02689024TerminatedAgnosia

    recruitment too slow; intervention was standard care in patients who were not included; acute care pathways changed due to policy regarding hip fracture patients

  • NCT03691935TerminatedAgnosia

    Slow enrollment related to global pandemic and changes to surgical practice.

All 16

Who is developing Ropivacaine?

2 companies: TLC Biopharmaceuticals and PHARMAFINA.

Companies
  • TLC BiopharmaceuticalsPhase 2postsurgical pain management
  • PHARMAFINAPhase 1nerve block

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 1Nov 2026: 02 papers in 12 months
Research Square

Sedative reduced delirium after hip fracture surgery

In a preprint trial, delirium occurred in 21.2% of older patients given the sedative versus 45.7% given placebo within seven days of hip fracture surgery.In a preprint trial, delirium occurred in 21.2% of older patients given the sedative versus 45.7% given placebo within seven days of hip fracture surgery.

Preprint: randomized trial · 490 peoplePostoperative delirium
Paper

See all 12

Related